Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 30Carcinoma, Hepatocellular 13Rectal Neoplasms 5Sarcoma, Ewing 4Osteosarcoma 4Gastrointestinal Stromal Tumors 4Colonic Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Glioblastoma 3Sarcoma 2Neoplasms 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Esophageal Neoplasms 2Chondrosarcoma 2Bone Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Solid Malignant Tumors 1Small Cell Lung Carcinoma 1Recurrence 1Piebaldism 1Patient Compliance 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

regorafenib 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
MSI-H Colorectal Cancer × regorafenib × 1 year × Clear all
NCT06006923 2026-01-20

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

University of Pittsburgh

Phase 2 Terminated
1 enrolled
GastrointestinalOther solid neoplasm

MSI-H Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡